| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| UCB | 2 | - | -0,36 % | ||
| AB INBEV | 1 | 30 | +0,27 % | ||
| UMICORE | 1 | 2 | -1,72 % | ||
| APERAM | 1 | - | -2,61 % | ||
| ARGENX | - | 10 | +1,09 % | ||
| MELEXIS | - | 4 | -4,44 % | ||
| ELIA GROUP | - | 4 | -2,26 % | ||
| AGEAS | - | 1 | +0,16 % | ||
| KBC GROEP NV | - | 1 | -0,91 % | ||
| GBL | - | 1 | -0,65 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:42 | Aperam delivered balanced performance despite challenging market conditions in 2025 | 7 | SteelRadar | ||
| Fr | Anheuser-Busch InBev SA/NV - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| Fr | UCB SA Reports Long-Term Bimzelx Data In Hidradenitis Suppurativa | 240 | AFX News | BRUSSELS (dpa-AFX) - UCB S.A. (UCBJY) announced on Friday that it has presented new post hoc data regarding Bimzelx (bimekizumab) at the American Academy of Dermatology Annual Meeting 2026 held... ► Artikel lesen | |
| Fr | Umicore: Notice of ordinary and extraordinary shareholders' meetings and publication of the Annual Report 2025 | 3 | GlobeNewswire (USA) | ||
| Fr | UCB Announces New BIMZELX (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa | 376 | PR Newswire | Symptom control throughout three years: 86.1% of people living with moderate-to-severe hidradenitis suppurativa (HS) treated with BIMZELX had no acute exacerbation of symptoms, known... ► Artikel lesen | |
| Fr | Sofina FY25 Profit Declines | 222 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sofina Société Anonyme (SOF.BR) reported that its net result for fiscal 2025 was 113.00 million euros, a sharp decrease from 1.36 billion euros, previous... ► Artikel lesen | |
| Fr | AB InBev Chair Martin Barrington set to retire after extended tenure | 12 | Alliance News | ||
| Fr | ANHEUSER-BUSCH INBEV SA/NV - Notice of Annual General Meeting | 4 | SENS | ||
| Fr | ANHEUSER-BUSCH INBEV SA/NV - AB InBev Announces the Retirement of Longstanding Chairman Martin J. Barrington | 4 | SENS | ||
| Fr | UCB - Convening Notice to the General Meeting of the Shareholders 2026 | 318 | GlobeNewswire (Europe) | CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS
The Board of Directors invites the shareholders to the general meeting of the shareholders (the "General Meeting") which will be held on Thursday... ► Artikel lesen | |
| Do | Syensqo SA: Syensqo notifies bondholders of the Redemption Price for its €500 million senior bonds | 364 | GlobeNewswire (Europe) | Regulated information
Syensqo notifies bondholders of the Redemption Price for its €500 million senior bondsBrussels, March 26, 2026 - 6.15 pm CET
Following the publication by the Issuer... ► Artikel lesen | |
| Do | Syensqo SA: Syensqo successfully completes its LTI Share Buyback Program | 241 | GlobeNewswire (Europe) | Press releaseCommuniqué de pressePersbericht
Regulated
Syensqo successfully completes its LTI Share Buyback Program
Brussels, Belgium - March 26, 2026 18:00 CET
Syensqo is pleased to... ► Artikel lesen | |
| Do | Für Europas Leiterplattenfertigung: Umicore bringt modernen Kupferprozess nach Mazedonien | 13 | elektroniknet | ||
| Do | Aperam S.A.: Aperam announces the publication of its Annual Report 2025 | 224 | Dow Jones News | DJ Aperam announces the publication of its Annual Report 2025
Aperam S.A. / Key word(s): Annual Results/Annual Results
Aperam announces the publication of its Annual Report 2025
26-March-2026... ► Artikel lesen | |
| Mi | $100 Invested In argenx 5 Years Ago Would Be Worth This Much Today | 8 | Benzinga.com | ||
| Mi | UCB banks on Georgia for $2bn biologics manufacturing facility | 7 | Pharmaceutical Technology | ||
| Mi | UCB to Build New U.S. Biologics Manufacturing Facility in Georgia | 2 | Contract Pharma | ||
| Mi | UCB announces plans to build drug manufacturing plant in US | 2 | belga | ||
| Mi | Aedifica NV/SA: 2025 Annual Report | 11 | GlobeNewswire (USA) | ||
| Di | UCB unveils plan to build huge biologics plant near its US headquarters in Atlanta | 2 | FiercePharma |